Table 1.
characteristic | No. of patients | % |
---|---|---|
Age(yrs) | ||
Median | 54.0 | |
Range | 26.0-79.0 | |
Sex | ||
Male | 49 | 61.3 |
Female | 31 | 38.7 |
ECOG performance status | ||
0 | 36 | 45.0 |
1 | 42 | 52.5 |
2 | 2 | 2.5 |
Primary sites | ||
Cardia | 21 | 26.3 |
Body | 18 | 22.5 |
Antrum/pylorus | 41 | 51.2 |
Metastatic sites | ||
Liver | 26 | 32.5 |
Lung | 21 | 26.3 |
Peritoneum | 19 | 23.8 |
Others | 14 | 17.4 |
Pathologic differentiation N0 | ||
G1 | 2 | 2.5 |
G2 | 26 | 32.5 |
G3 | 52 | 65.0 |
Treatment Response (1st line) | ||
CR | 2 | 2.5 |
PR | 36 | 45.0 |
SD | 24 | 30.0 |
PD | 18 | 22.5 |
2nd-line chemotherary regimen | ||
BSC | 57 | 71.3 |
FOLFIRI | 6 | 7.5 |
XELIRI | 8 | 10.0 |
DX | 6 | 7.5 |
TP | 3 | 3.7 |
CR, complete response; PR, partial response; SD, stable disease; PD, progression disease;
BSC, best supportive care; FOLFIRI, 5-fluracil plus leucovorin plus irinotecan; XELIRI, capecitabine plus irinotecan; DX, docitaxel plus capecitabine; TP, paclitaxel plus cisplatin.